| Last Price | 42.66 | Max Price | 46.14 |
| Min Price | 23.51 | 1 Year return | 5.28 |
| Sector | Health Care | Subsector | Biotechnology |
| Year | Turnover | Total sector | Market share |
|---|---|---|---|
| 2019 | 107 | 136,070 | 0.08 % |
| 2020 | 96 | 153,065 | 0.06 % |
| 2021 | 193 | 227,669 | 0.08 % |
| 2022 | 277 | 260,393 | 0.11 % |
| 2023 | 327 | 215,054 | 0.15 % |
No Records Found
No Records Found
No Records Found
Over the last 12 months, that were profitable period for the investors in Veracyte Inc, the stock gained around 1 percent. Over the period from December 2011 till December 2016 the stock lost on average 0 percent. Veracyte Inc's revenues between 2011 and 2015 were very volatile and moved between 11,63 million dollars and 49,5 million dollars. The net results between 2011 and 2015 were far from constant and fluctuated between -14,45 million dollars and -33,7 million dollars.
Veracyte Inc is active in the health care eq. & services sector. Over the past 10 years the global health care companies gained around 102 percent. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-2016) there is a plus of 102 percent.
Over the past 5 years the American company paid out dividends.
At the end of 2015 the American company had a balance sheet of around 75,29 million dollars. 24,04 million dollars (31,93 percent of the total balance sheet) was financed by debt. At the end of 2015 the health care company's stock was traded with a price/earnings-ratio -7. So the stock' value was -7 times the 2015' earnings per share. Based on the classical stock valuation theories the American stock can be seen as a value stock.
At the end of 2015 the health care company's market capitalization (the number of shares times the market price) equaled around 176,5 million dollars. At the end of 2015 the American company had around 25,99 million stocks listed on the exchanges.
All Veracyte Inc's financial reports are located here. More information about Veracyte Inc can be found it's website. .
| Results |
2021
|
2022
|
2023
|
2024
|
2025
|
|---|---|---|---|---|---|
| Revenue |
|
|
|
|
|
| Costs |
|
|
|
|
|
| Profit |
|
|
|
|
|
| Margin of profit |
|
|
|
|
|
| ROI |
|
|
|
|
|
| Balance |
2021
|
2022
|
2023
|
2024
|
2025
|
|---|---|---|---|---|---|
| Equity |
|
|
|
|
|
| Debt |
|
|
|
|
|
| Total assets |
|
|
|
|
|
| Solvency |
|
|
|
|
|
| Cash |
|
|
|
|
|
| Cashflow |
|
|
|
|
|
| Employees |
|
|
|
|
|
| Revenue per employee |
|
|
|
|
|
| Cashflow / Debt |
|
|
|
|
|
| Details |
2016
|
2017
|
2018
|
2019
|
2020
|
|---|---|---|---|---|---|
| Price |
7.74
|
6.53
|
12.58
|
27.92
|
48.94
|
| Eps |
-1.03
|
-0.76
|
-0.54
|
-0.24
|
-0.54
|
| Price/earnings-ratio |
-7.51
|
-8.59
|
-23.30
|
-116.33
|
-77.20
|
| Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
| Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
| Book value |
1.68
|
0.91
|
1.70
|
4.30
|
5.93
|
| Market to book |
0.22
|
0.14
|
0.14
|
0.15
|
0.14
|
| Cashflow per stock |
-0.79
|
-0.58
|
-0.29
|
-0.06
|
-0.14
|
| Stocks |
34
|
34
|
41
|
50
|
58
|
| Market Cap |
261.32
|
223.39
|
514.06
|
1.385.54
|
2.426.38
|
|
Date
|
Price
|
|---|---|
|
12 Nov 2025
|
42.66
|
|
11 Nov 2025
|
42.35
|
|
06 Nov 2025
|
41.69
|
|
05 Nov 2025
|
36.12
|
|
04 Nov 2025
|
36.45
|
|
29 Oct 2025
|
35.60
|
|
23 Oct 2025
|
36.10
|
|
18 Oct 2025
|
35.83
|
|
09 Oct 2025
|
35.10
|
|
03 Oct 2025
|
35.63
|
|
30 Sep 2025
|
33.61
|
|
22 Sep 2025
|
34.11
|
|
16 Sep 2025
|
31.87
|
|
08 Sep 2025
|
32.43
|
|
01 Sep 2025
|
30.34
|
|
21 Aug 2025
|
29.49
|
|
15 Aug 2025
|
30.04
|
|
07 Aug 2025
|
23.97
|
|
23 Jul 2025
|
23.51
|
|
18 Jul 2025
|
23.51
|
|
17 Jul 2025
|
24.22
|
|
16 Jul 2025
|
25.17
|
|
15 Jul 2025
|
25.24
|
|
14 Jul 2025
|
26.65
|
|
11 Jul 2025
|
27.08
|
|
10 Jul 2025
|
27.52
|
|
09 Jul 2025
|
27.08
|
|
08 Jul 2025
|
26.58
|
|
07 Jul 2025
|
26.34
|
|
03 Jul 2025
|
27.51
|